V on Willebrand factor (VWF) is a multimeric glycoprotein whose circulating plasma levels vary significantly within and between individuals. These variations have been associated with ABO blood type, estrogen levels, age and stress. [1] [2] [3] [4] In particular, ABO blood type exerts a major effect on plasma VWF levels. Recent studies have demonstrated that individuals carrying one O allele (AO and BO) have significantly lower plasma levels of VWF and FVIII than those carrying no O allele (AA, AB and BB). 5 The antigens of the ABO system consist of complex carbohydrate molecules. The A and B alleles encode A and B glycosyltransferase, which convert H antigen into A or B determinants. Group O individuals lack transferase enzymes and, consequently, continue to express H antigen. 6 In addition to the common phenotypes A 1 9 The aim of this study was to correlate ABO groups and rare subgroups with plasma levels of factor VIII (FVIII), von Willebrand factor (VWF:Ag), and ristocetin cofactor (VWF:RCo).
Design and Methods
Samples from 114 blood donors with known blood groups and subgroups were submitted to ABO serology and molecular analysis, VWF:Ag and FVIII dosages and ristocetin cofactor assay. The donors were males with no history of taking drugs. The age of the donors ranged from 18-60 years old (median age 32). The donors were instructed regarding the nature and non-compulsory character of the research, and signed informed consent was obtained prior to collecting samples. This study was approved by the Research Ethics Committee of the State University of Campinas and Brazilian Medical Research Committee. Blood was drawn by venipuncture into evacuated siliconized glass tubes containing 3.2% sodium citrate, in a ratio of 1:9 with blood, for ristocetin cofactor assay, VWF:Ag and factor VIII dosages. Blood processing was completed within 2 hours. Blood samples for ABO serology and molecular analysis were collected according to standard blood banking practice.
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ABO phenotypes were determined by agglutination and adsorption-elution tests using monoclonal and polyclonal anti-A, B and AB antibodies (Asem-NPBI, Itapecirica da Serra, São Paulo Brazil; DiaMed SA, Cressier s/Morat, Suisse; DiaMed Latino América, Lagoa Santa, Brazil). H antigen was determined using anti-H lectin from Ulex europaeus (DiaMed Latino América, Lagoa Santa, Brazil) and the agglutination reaction intensity was evaluated according to Marsh et al. 11 Serum screening for isoagglutinins and antibodies was performed by tube agglutination tests at 4°C and 22°C and by standardized serological procedures with a microtyping system (DiaMed SA, Cressier s/Morat, Suisse).
10 Saliva testing was performed using a technique described elsewhere.
Subgroup serologic status was defined according to Daniels. 7 Genomic DNA was extracted from blood conserved with EDTA using the standard phenol-chloroform technique. ABO genotyping was performed by polymerase chain reaction (PCR) amplification of exons 6 and 7 of the ABO gene, followed by diagnostic restriction enzyme digestion. Four different primers were used to amplify two fragments, each spanning a different polymorphic site of the ABO gene. Primers, exon 6: P1-5´-TGCCAG -CTCCATGTGACCGC 3´ (sense), P2-5´ TCGCCACTGC-CTGGGTCTCTAC 3´ (antisense); exon 7: P3-5´ CCGTC-CGCCTGCCTTGCAG 3´ (sense), P4-5´ TGCCGGCAG -CCCTCCCAGAG 3' (antisense). Primers P1/P2 in conjunction with the restriction enzyme KpnI and BstE I were used to differentiate the O 1 allele from the A, B and O 2 alleles.
12 Primers P3/P4 in conjunction with the restriction enzyme AluI were used to differentiate the A 2 from the A1 allele. These same primers with the restriction enzyme MboI were used to discriminate the AX from A 1 , A 2 and A 3 alleles. 13 A3(3) and Bel(1) serological and genetic molecular studies were previously described.
14, 15 The ABO alleles are named according to the nomenclature used in the Blood Group Antigen Gene Mutation Database (http://www.bioc.
aecom.yu.edu/bgmut/abo.htm).
Factor VIII coagulant was measured by a one stage clothing method using a factor-VIII deficient substrate.
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The activity of vWF was measured by ristocetin cofactor assay -VWF:RCo -(Helena Laboratories, Beaumont, Texas, USA). VWF:Ag was measured by an enzymelinked immunosorbent assay (ELISA) using polyclonal antiserum (Dako, Denmark). Lyophilised commercial reference preparations of VWF:Ag, FVIII and VWF:RCo, standardized against the World Health Organization standard, were used as the standards in this study.
Statistical analysis
Statistical analysis was performed using Wilcoxon's rank sum test and Spearman´s rank correlation. p values ≤0.05 were considered statistically significant.
Results and Discussion
The ABO serological and genotype distribution were AA (n=10), BB (n=10), AB (n=10), AO 1 1 (p=0.029). The results also showed higher VWF levels in A 2 B individuals (median: VWF:Ag=169%) than in the AA, AB and BB groups (p=0.013) ( Figure 1A) .
Overall, there was a strong correlation between VWF:Ag and FVIII levels (R=0.77; p=0.001) and between VWF:Ag and VWF:RCo levels (R=0.75; p=0.001) (Spearman's rank correlation).
This study was carried out to assess FVIII, VWF:Ag and VWF:RCo in 114 healthy male blood donors. It was restricted to males to avoid possible estrogen-related effects, although gender differences in FVIII and VWF:Ag were not seen in two previous studies of younger populations.
3,17 Our data demonstrated a strong correlation between VWF:Ag plasma levels and FVIII and also between VWF:Ag and VWF:RCo. The donors were ABO genotyped and the results clearly showed a significant linkage between the ABO locus and VWF antigen (p=0.001). Subjects with H-antigen-rich blood groups had significantly lower levels of FVIII and VWF:Ag antigen than did individuals with H-antigen-poor groups. . These subgroups are, however, rare and thus the study numbers were small (eight cases). Previous reports have demonstrated that the normal range of VWF:Ag found in group O individuals reaches below 50 IU/dL.
8 Unless ABO group-specific VWF:Ag references ranges are used, normal group O and also ABO subgroup individuals could be identifying as having a level of VWF below the normal reference range and therefore at potential risk of bleeding. These results favor the hypothesis that the expression of H antigen on VWF is one of the most important determinants of circulating levels of VWF:Ag. 8 In conclusion, we demonstrated that the circulating levels of VWF:Ag and FVIII in subjects with rare subgroups were similar to those found in group O individuals. These data could contribute to the diagnosis of von Willebrand's disease and to the evaluation of thrombophilia in individuals with different ABO subgroups. 
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